NESINA MET 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

nesina met 12.5/500; 12.5 mg alogliptin (as benzoate) / 500 mg metformin hydrochloride film-coated tablets blister pack

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 500 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; mannitol; titanium dioxide; magnesium stearate; iron oxide yellow; purified talc; crospovidone; povidone; hypromellose - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

NESINA MET 12.5/850; 12.5 mg alogliptin (as benzoate) / 850 mg metformin hydrochloride film-coated tablets blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

nesina met 12.5/850; 12.5 mg alogliptin (as benzoate) / 850 mg metformin hydrochloride film-coated tablets blister pack

takeda pharmaceuticals australia pty ltd - metformin hydrochloride, quantity: 850 mg; alogliptin benzoate, quantity: 17 mg (equivalent: alogliptin, qty 12.5 mg) - tablet, film coated - excipient ingredients: titanium dioxide; purified talc; microcrystalline cellulose; povidone; mannitol; crospovidone; hypromellose; iron oxide yellow; magnesium stearate - nesina met is indicated to improve glycaemic control in adult patients (> or = 18 years old) with type 2 diabetes mellitus when diet and exercise do not provide adequate glycaemic control and treatment with both alogliptin and metformin is appropriate,,- when treatment with metformin alone does not provide adequate control; or - in combination with a thiazolidinedione or with insulin, when dual therapy does not provide adequate control.,nesina met can also be used to replace separate tablets of alogliptin and metformin in patients already being treated with this combination.

METFORMIN ARW XR metformin hydrochloride 500 mg extended release tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

metformin arw xr metformin hydrochloride 500 mg extended release tablet blister pack

arrotex pharmaceuticals pty ltd - metformin hydrochloride, quantity: 500 mg - tablet, modified release - excipient ingredients: carmellose sodium; ethanol; magnesium stearate; microcrystalline cellulose; hypromellose; colloidal anhydrous silica - treatment of type 2 diabetes mellitus in adults, particularly in overweight patients, when dietary management and exercise alone does not result in adequate glycaemic control. metformin arw xr may be used as monotherapy or in combination with other oral antidiabetic agents, or with insulin.

METFORMIN RANBAXY metformin hydrochloride 500 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

metformin ranbaxy metformin hydrochloride 500 mg tablet blister pack

generic health pty ltd - metformin hydrochloride -

METFORMIN HYDROCHLORIDE tablet United States - English - NLM (National Library of Medicine)

metformin hydrochloride tablet

aphena pharma solutions - tennessee, llc - metformin hydrochloride (unii: 786z46389e) (metformin - unii:9100l32l2n) - metformin hydrochloride 500 mg - metformin hcl tablets, usp are indicated as an adjunct to diet and exercise to improve glycemic control in adults and children with type 2 diabetes mellitus. metformin hcl, usp is contraindicated in patients with: 1. renal disease or renal dysfunction (e.g., as suggested by serum creatinine levels ≥1.5 mg/dl [males], ≥1.4 mg/dl [females] or abnormal creatinine clearance) which may also result from conditions such as cardiovascular collapse (shock), acute myocardial infarction, and septicemia (see warnings and precautions). 2. known hypersensitivity to metformin hcl, usp. 3. acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma. diabetic ketoacidosis should be treated with insulin. metformin hcl, usp should be temporarily discontinued in patients undergoing radiologic studies involving intravascular administration of iodinated contrast materials, because use of such products may result in acute alteration of renal function. (see also precautions.)

APO-METFORMIN 1000 metformin hydrochloride 1000 mg tablet blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

apo-metformin 1000 metformin hydrochloride 1000 mg tablet blister pack

cipla australia pty ltd - metformin hydrochloride -

APO-METFORMIN 850 Australia - English - Department of Health (Therapeutic Goods Administration)

apo-metformin 850

cipla australia pty ltd - metformin hydrochloride -

APO-METFORMIN 500 Australia - English - Department of Health (Therapeutic Goods Administration)

apo-metformin 500

cipla australia pty ltd - metformin hydrochloride -

Metformin Denk 500 500mg tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

metformin denk 500 500mg tablets film-coated

denk pharma gmbh & co. kg - metformin (metformin hydrochloride) - tablets film-coated - 500mg

Metformin Denk 500 tablets film-coated Armenia - English - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

metformin denk 500 tablets film-coated

denk pharma gmbh & co. kg - metformin (metformin hydrochloride) - tablets film-coated - 500mg